Eden Biopharma (06998.HK): First-in-human Phase I clinical study data for GB268 released at the 2026 ESMO Congress

Zhitong Finance APP News, Edding Jihe (06998.HK) announced that the preliminary data from the first-in-human Phase I clinical study of GB268 were presented in a poster session (Number: 1963P) at the 2026 European Society for Medical Oncology (ESMO) Congress. The study evaluated the safety and tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of GB268 monotherapy in patients with previously treated advanced solid tumors.